Opendata, web and dolomites

SPELITEC SIGNED

Sequence sPecific ELImination of shiga-Toxin E. Coli

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SPELITEC project word cloud

Explore the words cloud of the SPELITEC project. It provides you a very rough idea of what is the project "SPELITEC" about.

tests    microbiota    shiga    team    orally    disrupting    model    initiate    bacterial    infections    clinical    toxin    company    release    hospitalized    patients    license    companies    stecs    complete    spelitec       alternative    complications    first    pharma    acquisition    medical    progression    mechanism    strains    multinational    inducing    consisting    safety    eb003    animals    nature    orphan    patient    humans    young    therapeutic    stec    disease    indication    eligo    primary    capsid    conducting    multivalent    uremic    producing    haemolytic    coupled    solid    validate    launch    rehydration    fatal    administered    spectrum    symptomatic    validation    drug    antibodies    exert    plans    resistance    finalise    individualised    clinically    preclinical    safe    paediatric    pharmacological    batch    designed    mix    eliminates    dialysis    gel    mutation    toxicity    toxins    treatments    selectively    coli    variants    children    bacteria    elimination    treatment    compound    market    validated    action    authorization    receive    background    antibiotic    receptors    populations    liquid    transfusions    unmet    business    healthy    empts   

Project "SPELITEC" data sheet

The following table provides information about the project.

Coordinator
ELIGO BIOSCIENCE 

Organization address
address: 29 RUE FAUBOURG SAINT JACQUES PEPIN
city: PARIS
postcode: 75014
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙948˙250 €
 EC max contribution 2˙763˙775 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2021-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELIGO BIOSCIENCE FR (PARIS) coordinator 2˙763˙775.00

Map

 Project objective

SPELITEC is the first treatment for Shiga toxin-producing E. coli (STEC) infections, which affects primary young children and can be fatal in 1-5% of the cases. Currently there is no validated safe treatment: hospitalized patients receive only symptomatic treatments consisting of rehydration coupled with transfusions and dialysis for haemolytic uremic complications. The SPELITEC program is designed to finalise preclinical and initiate clinical studies for elimination of STEC bacteria (Shiga-toxin producing E. coli) in paediatric populations with a dedicated product: EB003. EB003 selectively eliminates STEC bacteria early in the disease progression; it is not expected to exert any toxicity in humans or animals; it is a multivalent mix of different capsid variants allows to target the whole spectrum of clinically relevant strains and pre-empts the acquisition of resistance through mutation of bacterial receptors; it is administered orally by a liquid/gel which is patient-friendly and adapted to young children and it represents a cost-effective alternative to antibodies against Shiga toxins. Our technology is the only one allowing the specific elimination of STECs without toxin release and without disrupting microbiota and inducing antibiotic resistance. Eligo will complete early drug development, which should ensure market authorization given the orphan and unmet medical need nature of the indication, and plans to out-license the compound to an established pharma company that will launch the product on the market. The management team of Eligo has solid business and technical management experience in multinational companies and a very strong drug development background. During the Phase 2 project we will validate this new individualised therapeutic approach and mechanism of action by conducting the validation of the pharmacological model, the production of a clinical batch and the safety tests in healthy animals.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPELITEC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPELITEC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Savesight (2020)

Contact lens embedded sensor for ocular hypertension and glaucoma monitoring

Read More  

ECOBIOMASS (2019)

Achieving unique wines through an efficient production process

Read More  

Proteus 25 (2018)

Developing the world’s first food wrapping machine with organic film

Read More